Pietschmann Thomas

List of Publications by Year
in descending order

171	17,912	23567 58	13379 130
papers	citations	h-index	g-index

183	183	183	15848
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sandacrabins â€“ Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium**. Chemistry - A European Journal, 2022, 28, e202104484.	3.3	10
2	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity, 2022, 55, 341-354.e7.	14.3	21
3	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. Virus Evolution, 2022, 8, veac007.	4.9	10
4	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. Journal of Virology, 2022, 96, e0199521.	3.4	4
5	Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements. Journal of Virology, 2021, 95, .	3.4	13
6	Magnesium Complexes of Ladanein: A Beneficial Strategy for Stabilizing Polyphenolic Antivirals. European Journal of Inorganic Chemistry, 2021, 2021, 2764-2772.	2.0	1
7	Characterization of RNA Sensing Pathways in Hepatoma Cell Lines and Primary Human Hepatocytes. Cells, 2021, 10, 3019.	4.1	10
8	Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036830.	6.2	40
9	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS ONE, 2020, 15, e0236447.	2.5	7
10	Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	10.3	23
11	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
12	The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathogens, 2020, 16, e1008554.	4.7	25
13	Controlled Functional Zonation of Hepatocytes In Vitro by Engineering of Wnt Signaling. ACS Synthetic Biology, 2020, 9, 1638-1649.	3.8	13
14	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. Gut, 2020, 69, 1659-1666.	12.1	18
15	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. Antiviral Research, 2020, 177, 104774.	4.1	30
16	Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Medical Microbiology and Immunology, 2020, 209, 499-514.	4.8	6
17	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. Cells, 2019, 8, 610.	4.1	5
18	HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. Cells, 2019, 8, 233.	4.1	41

#	Article	IF	Citations
19	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. Viruses, 2019, 11, 275.	3.3	7
20	Physicochemical Properties Govern the Activity of Potent Antiviral Flavones. ACS Omega, 2019, 4, 4871-4887.	3.5	11
21	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. Journal of Hepatology, 2019, 70, 1082-1092.	3.7	15
22	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
23	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research, 2018, 248, 53-62.	2.2	124
24	The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
25	CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells. Viruses, 2018, 10, 207.	3.3	13
26	Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathogens, 2018, 14, e1007111.	4.7	46
27	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Research, 2017, 139, 129-137.	4.1	5
28	Protein Interactions during the Flavivirus and Hepacivirus Life Cycle. Molecular and Cellular Proteomics, 2017, 16, S75-S91.	3.8	53
29	Immune protection against reinfection with nonprimate hepacivirus. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2430-E2439.	7.1	42
30	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. Journal of Hepatology, 2017, 67, 480-489.	3.7	51
31	Virucidal Activity of World Health Organizationâ€“Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. Journal of Infectious Diseases, 2017, 215, 902-906.	4.0	151
32	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Research, 2017, 147, 19-28.	4.1	28
33	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. Journal of Virology, 2017, 91, .	3.4	21
34	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Letters, 2017, 6, 935-940.	4.8	4
35	Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. Journal of Virology, 2017, 91, .	3.4	19
36	Flunarizine prevents hepatitis C virus membrane fusion in a genotypeâ€dependent manner by targeting the potential fusion peptide within E1. Hepatology, 2016, 63, 49-62.	7.3	64

#	Article	IF	Citations
37	cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. Cell Host and Microbe, 2016, 20, 443-457.	11.0	46
38	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. Journal of Virology, 2016, 90, 10670-10681.	3.4	27
39	Hepatitis C virus plays hide and seek with neutralizing antibodies. Hepatology, 2016, 64, 1840-1842.	7.3	7
40	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. Hepatology, 2016, 64, 2274-2276.	7.3	7
41	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. MBio, 2016, 7, .	4.1	13
42	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2132-2139.	3.2	75
43	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. Journal of Virology, 2016, 90, 5075-5089.	3.4	4
44	Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. Journal of Virology, 2016, 90, 3065-3073.	3.4	22
45	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8 ⁺ T Cell Response by Selection of Altered Epitope Processing. Journal of Virology, 2016, 90, 33-42.	3.4	16
46	Decoding protein networks during virus entry by quantitative proteomics. Virus Research, 2016, 218, 25-39.	2.2	24
47	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut, 2016, 65, 2029-2034.	12.1	21
48	ABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus Production. PLoS Pathogens, 2016, 12, e1005568.	4.7	26
49	Hepatitis C Virus Stimulates Murine CD8Î±-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathogens, 2016, 12, e1005736.	4.7	4
50	Cell culture-derived HCV cannot infect synovial fibroblasts. Scientific Reports, 2015, 5, 18043.	3.3	1
51	Interferonâ€inducible cholesterolâ€25â€hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology, 2015, 62, 702-714.	7.3	78
52	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses, 2015, 7, 3995-4046.	3.3	42
53	Efficient Virus Assembly, but Not Infectivity, Determines the Magnitude of Hepatitis C Virus-Induced Interferon Alpha Responses of Plasmacytoid Dendritic Cells. Journal of Virology, 2015, 89, 3200-3208.	3.4	9
54	Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. Cell Reports, 2015, 12, 864-878.	6.4	50

#	Article	IF	Citations
55	Clinical course of infection and viral tissue tropism of hepatitis C virusâ€“like nonprimate hepaciviruses in horses. Hepatology, 2015, 61, 447-459.	7.3	116
56	Control of Hepatitis C Virus Replication in Mouse Liver-Derived Cells by MAVS-Dependent Production of Type I and Type III Interferons. Journal of Virology, 2015, 89, 3833-3845.	3.4	23
57	Mechanisms of Methods for Hepatitis C Virus Inactivation. Applied and Environmental Microbiology, 2015, 81, 1616-1621.	3.1	46
58	Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure. Alimentary Pharmacology and Therapeutics, 2015, 41, 532-543.	3.7	9
59	Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. Journal of Hepatology, 2015, 63, 813-821.	3.7	28
60	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. Journal of General Virology, 2015, 96, 2636-2642.	2.9	19
61	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS ONE, 2015, 10, e0134529.	2.5	30
62	A molecular tweezer antagonizes seminal amyloids and HIV infection. ELife, 2015, 4, .	6.0	71
63	In sero veritas: what serum markers teach us about HCV infection of primary human hepatocytes. Gut, 2014, 63, 1375-1377.	12.1	2
64	Natural reservoirs for homologs of hepatitis C virus. Emerging Microbes and Infections, 2014, 3, 1-9.	6.5	88
65	Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion. Viruses, 2014, 6, 1149-1187.	3.3	56
66	A circuit of paracrine signals between liver sinusoid endothelial cells and hepatocytes regulates hepatitis C virus replication. Hepatology, 2014, 59, 363-365.	7.3	0
67	Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. Journal of Virology, 2014, 88, 667-678.	3.4	2
68	The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets. Digestive Diseases, 2014, 32, 525-537.	1.9	3,128
69	Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies. PLoS ONE, 2014, 9, e102235.	2.5	8
70	Apolipoprotein E Codetermines Tissue Tropism of Hepatitis C Virus and Is Crucial for Viral Cell-to-Cell Transmission by Contributing to a Postenvelopment Step of Assembly. Journal of Virology, 2014, 88, 1433-1446.	3.4	88
71	Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology, 2014, 59, 78-88.	7.3	40
72	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut, 2014, 63, 1137-1149.	12.1	148

#	Article	IF	Citations
73	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants within vitroresistance to SR-BI-targeting agents. Hepatology, 2014, 60, 1508-1518.	7.3	50
74	Role of Hypervariable Region 1 for the Interplay of Hepatitis C Virus with Entry Factors and Lipoproteins. Journal of Virology, 2014, 88, 12644-12655.	3.4	42
75	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. Antiviral Research, 2014, 110, 52-59.	4.1	12
76	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. Hepatology, 2014, 60, 508-520.	7.3	7
77	Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology, 2014, 59, 24-34.	7.3	54
78	Entry and replication of recombinant hepatitis C viruses in cell culture. Methods, 2013, 59, 233-248.	3.8	46
79	Hepatitis C Virus Replication in Mouse Cells Is Restricted by IFN-Dependent and -Independent Mechanisms. Gastroenterology, 2013, 145, 1414-1423.e1.	1.3	30
80	Stability and transmission of hepatitis CÂvirus in different anesthetic agents. American Journal of Infection Control, 2013, 41, 942-943.	2.3	3
81	Interferon lambda 4 signals via the IFNÎ» receptor to regulate antiviral activity against HCV and coronaviruses. EMBO Journal, 2013, 32, 3055-3065.	7.8	177
82	Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. Journal of Viral Hepatitis, 2013, 20, 478-485.	2.0	17
83	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. Current Hepatitis Reports, 2013, 12, 200-213.	0.3	7
84	Antiâ€infective properties of epigallocatechinâ€3â€gallate (<scp>EGCG</scp>), a component of green tea. British Journal of Pharmacology, 2013, 168, 1059-1073.	5.4	415
85	Two pathogen reduction technologiesâ€”methylene blue plus light and shortwave ultraviolet lightâ€”effectively inactivate hepatitis C virus in blood products. Transfusion, 2013, 53, 1010-1018.	1.6	54
86	Cell Culture Systems for Hepatitis C Virus. Current Topics in Microbiology and Immunology, 2013, 369, 17-48.	1.1	72
87	Characterization of the inhibition of hepatitis C virus entry byIn vitro-generated and patient-derived oxidized low-density lipoprotein. Hepatology, 2013, 57, 1716-1724.	7.3	16
88	Hepatitis C virus NS5B polymerase primes innate immune signaling. Hepatology, 2013, 57, 1275-1277.	7.3	2
89	Hepatitis C Virus p7 is Critical for Capsid Assembly and Envelopment. PLoS Pathogens, 2013, 9, e1003355.	4.7	102
90	Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk. Journal of Infectious Diseases, 2013, 208, 1943-1952.	4.0	47

#	Article	IF	Citations
91	Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. Journal of Infectious Diseases, 2013, 207, 281-287.	4.0	57
92	Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment. Journal of Virology, 2013, 87, 13297-13306.	3.4	18
93	Subcellular Localization and Function of an Epitope-Tagged p7 Viroporin in Hepatitis C Virus-Producing Cells. Journal of Virology, 2013, 87, 1664-1678.	3.4	42
94	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology, 2013, 57, 492-504.	7.3	66
95	Interferon Î±â€“Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. Journal of Infectious Diseases, 2012, 205, 1351-1362.	4.0	38
96	MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles. PLoS Pathogens, 2012, 8, e1002829.	4.7	110
97	Escape from a Dominant HLA-B*15-Restricted CD8 ⁺ T Cell Response against Hepatitis C Virus Requires Compensatory Mutations outside the Epitope. Journal of Virology, 2012, 86, 991-1000.	3.4	21
98	High Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant Mutants. Journal of Biological Chemistry, 2012, 287, 39224-39232.	3.4	20
99	Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors. Journal of Visualized Experiments, 2012, , e4029.	0.3	0
100	A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. Gastroenterology, 2012, 143, 213-222.e5.	1.3	111
101	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. Gastroenterology, 2012, 143, 223-233.e9.	1.3	66
102	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. Gastroenterology, 2012, 143, 439-447.e1.	1.3	30
103	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. Antiviral Research, 2012, 96, 51-58.	4.1	2
104	Specific Acquisition of Functional CD59 but Not CD46 or CD55 by Hepatitis C Virus. PLoS ONE, 2012, 7, e45770.	2.5	15
105	Total Synthesis of a Noricumazoleâ€…A Library and Evaluation of HCV Inhibition. Chemistry - A European Journal, 2012, 18, 9083-9090.	3.3	19
106	Bile Acids Specifically Increase Hepatitis C Virus RNA-Replication. PLoS ONE, 2012, 7, e36029.	2.5	23
107	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine, 2011, 17, 589-595.	30.7	631
108	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. Journal of Viral Hepatitis, 2011, 18, 562-570.	2.0	24

#	Article	IF	Citations
109	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Research, 2011, 89, 136-148.	4.1	41
110	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 2011, 54, 1947-1955.	7.3	255
111	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. Journal of Virology, 2011, 85, 7613-7621.	3.4	40
112	Prolonged Survival of Hepatitis C Virus in the Anesthetic Propofol. Clinical Infectious Diseases, 2011, 53, 963-964.	5.8	11
113	Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines. PLoS Pathogens, 2011, 7, e1002029.	4.7	23
114	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. Journal of Infectious Diseases, 2011, 204, 1830-1838.	4.0	90
115	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. PLoS ONE, 2011, 6, e24142.	2.5	9
116	Development of novel therapies for hepatitis C. Antiviral Research, 2010, 86, 79-92.	4.1	70
117	NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus. Journal of Biological Chemistry, 2010, 285, 31446-31461.	3.4	119
118	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. Journal of Virology, 2010, 84, 5751-5763.	3.4	201
119	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2010, 4, 63-79.	3.0	8
120	Mouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell Line. Journal of Virology, 2010, 84, 964-975.	3.4	50
121	How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides. Journal of Infectious Diseases, 2010, 201, 1859-1866.	4.0	72
122	Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors. PLoS Pathogens, 2010, 6, e1000978.	4.7	109
123	Hepatitis C Virus P7â€"A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy. Viruses, 2010, 2, 2078-2095.	3.3	44
124	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. Gastroenterology, 2010, 138, 1875-1884.	1.3	68
125	Interferon-Î±â€"Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 1885-1897.e10.	1.3	177
126	Virucidal activity of 2 alcohol-based formulations proposed as hand rubs byÂthe World Health Organization. American Journal of Infection Control, 2010, 38, 66-68.	2.3	34

#	Article	IF	Citations
127	Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations. PLoS Pathogens, 2009, 5, e1000475.	4.7	116
128	Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles. Journal of Biological Chemistry, 2009, 284, 17657-17667.	3.4	79
129	Characterization of Determinants Important for Hepatitis C Virus p7 Function in Morphogenesis by Using trans -Complementation. Journal of Virology, 2009, 83, 11682-11693.	3.4	65
130	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 295-308.	16.8	345
131	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 447.	16.8	1
132	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology, 2009, 50, 1638-1645.	7.3	108
133	Final entry key for hepatitis C. Nature, 2009, 457, 797-798.	27.8	28
134	Regulation of hepatitis C virus replication by microRNAs. Journal of Hepatology, 2009, 50, 441-444.	3.7	14
135	Full-Length Infectious HCV Chimeras. Methods in Molecular Biology, 2009, 510, 347-359.	0.9	8
136	CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. Journal of General Virology, 2009, 90, 48-58.	2.9	162
137	Efficient trans -Encapsidation of Hepatitis C Virus RNAs into Infectious Virus-Like Particles. Journal of Virology, 2008, 82, 7034-7046.	3.4	131
138	Structural and Functional Characterization of Nonstructural Protein 2 for Its Role in Hepatitis C Virus Assembly. Journal of Biological Chemistry, 2008, 283, 28546-28562.	3.4	135
139	The Suppressive Effect That Myriocin Has on Hepatitis C Virus RNA Replication Is Independent of Inhibition of Serine Palmitoyl Transferase. Journal of Infectious Diseases, 2008, 198, 1091-1093.	4.0	6
140	Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions. PLoS Pathogens, 2007, 3, e103.	4.7	290
141	Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes. Journal of Virology, 2007, 81, 4591-4603.	3.4	198
142	The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells. Journal of Virology, 2007, 81, 588-598.	3.4	201
143	Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology, 2007, 46, 330-338.	7.3	127
144	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology, 2007, 46, 1722-1731.	7.3	222

#	Article	IF	Citations
145	High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI. Journal of Biological Chemistry, 2006, 281, 18285-18295.	3.4	186
146	HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. Journal of Hepatology, 2006, 45, 5-12.	3.7	46
147	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology, 2006, 43, 592-601.	7.3	150
148	Characterization of the Prototype Foamy Virus Envelope Glycoprotein Receptor-Binding Domain. Journal of Virology, 2006, 80, 8158-8167.	3.4	21
149	Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses. Journal of Virology, 2006, 80, 5308-5320.	3.4	363
150	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7408-7413.	7.1	651
151	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine, 2005, 11, 791-796.	30.7	2,561
152	Efficient hepatitis C virus cell culture system: What a difference the host cell makes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9739-9740.	7.1	91
153	Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain. Journal of Virology, 2005, 79, 3187-3194.	3.4	208
154	Targeting of Hepatitis C Virus Core Protein to Mitochondria through a Novel C-Terminal Localization Motif. Journal of Virology, 2004, 78, 7958-7968.	3.4	144
155	Prototype Foamy Virus Envelope Glycoprotein Leader Peptide Processing Is Mediated by a Furin-Like Cellular Protease, but Cleavage Is Not Essential for Viral Infectivity. Journal of Virology, 2004, 78, 13865-13870.	3.4	49
156	Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs. Journal of Virology, 2004, 78, 3436-3446.	3.4	158
157	Application of the trak-Câ„¢ HCV core assay for monitoring antiviral activity in HCV replication systems. Journal of Virological Methods, 2004, 118, 23-31.	2.1	17
158	Novel Insights into Hepatitis C Virus Replication and Persistence. Advances in Virus Research, 2004, 63, 71-180.	2.1	243
159	Hepatitis C Virus Replication in Cell Culture. , 2004, , 108-122.		0
160	Determinants of foamy virus envelope glycoprotein mediated resistance to superinfection. Virology, 2003, 314, 243-252.	2.4	20
161	Tissue culture and animal models for hepatitis C virus. Clinics in Liver Disease, 2003, 7, 23-43.	2.1	29
162	Replication-Competent Hybrids between Murine Leukemia Virus and Foamy Virus. Journal of Virology, 2003, 77, 7677-7681.	3.4	6

#	Article	IF	Citations
163	Persistent and Transient Replication of Full-Length Hepatitis C Virus Genomes in Cell Culture. Journal of Virology, 2002, 76, 4008-4021.	3.4	330
164	Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14416-14421.	7.1	244
165	A Particle-Associated Glycoprotein Signal Peptide Essential for Virus Maturation and Infectivity. Journal of Virology, 2001, 75, 5762-5771.	3.4	112
166	Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs. Journal of Virology, 2001, 75, 1252-1264.	3.4	336
167	Interferon-Î± inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. Journal of General Virology, 2001, 82, 723-733.	2.9	210
168	Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO Journal, 2000, 19, 3436-3445.	7.8	38
169	An Evolutionarily Conserved Positively Charged Amino Acid in the Putative Membrane-Spanning Domain of the Foamy Virus Envelope Protein Controls Fusion Activity. Journal of Virology, 2000, 74, 4474-4482.	3.4	54
170	Specific Binding of Recombinant Foamy Virus Envelope Protein to Host Cells Correlates with Susceptibility to Infection. Virology, 1999, 255, 228-236.	2.4	19
171	Foamy Virus Capsids Require the Cognate Envelope Protein for Particle Export. Journal of Virology, 1999, 73, 2613-2621.	3.4	152